Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Trading Statement

30 Nov 2005 07:04

Original Investments PLC30 November 2005 Original Investments PLC ("Original Investments" or "the Company") Acrobot update An innovative medical device, enabling orthopaedic surgeons to accurately planand perform hip resurfacing surgery, has been granted a CE-mark by BSI'sCertification Panel. The surgical navigation product has been developed by TheAcrobot Company ("Acrobot") in which Original Investments, the AIM-quotedinvestment company, has a 25% shareholding. The device has been developed incollaboration with Corin Group PLC ("Corin"), and the CE-mark is themanufacturer's guarantee that the device meets all the required Europeanmanufacturing and safety standards. Acrobot develops surgical systems for minimally-invasive, bone-conservingorthopaedic surgery. The new device, called Acrobot(R) Navigation, is beingcommercialised by Corin, under the name of Wayfinder(R), to enable accurateimplantation of the company's metal on metal hip resurfacing implant.Clinical trials are to start immediately at a London hospital. Justin Cobb,Professor of Orthopaedics at Imperial College, will lead the alpha site. Twoadditional sites in the UK and a third in Australia will start evaluation of theAcrobot(R) Navigation system in the second quarter of 2006. The device will bein wider use from the second half of 2006. The Acrobot(R) Navigation system gives the surgeon the ability to accuratelyimplant hip resurfacing prostheses in a minimally invasive procedure. It differsfrom competitive products by using mechanical tracking rather than optical orelectromagnetic technologies, giving it a higher accuracy at a lower cost.Acrobot believes that this unique selling point will increase the use of thetechnology, making it accessible to a larger number of surgeons and patients.The Acrobot(R) Navigation system has been developed by the Acrobot team at thecompany's laboratories in London. Acrobot is seeking licensees and distributorsfor applications of Navigation to other orthopaedic procedures. It is the secondof a number of related products to be produced by Acrobot, having launched theAcrobot(R) Planner software and service last month. A third product planned forlaunch in 2006 is the Acrobot(R) Hands-On Robotic System, which has already beensuccessfully proven in clinic for unicompartmental knee arthroplasty. Enquiries to: Dr. Paula Gomes, Director of OperationsThe Acrobot Company Ltd, Tel: +44 (0)20 7403 5866, Email:enquiries@acrobot.co.ukor Terry Bond, Managing Director, Original Investments PLC 44 (0) 1235 834734.Email: tb@originalinvestments.com About The Acrobot Company Ltd The Acrobot Company Ltd develops precision surgical systems for minimallyinvasive, bone conserving, orthopaedic surgery. The Company was founded sixyears ago by Imperial Innovations as a collaboration to combine the skills ofclinicians and academics Using proprietary surgical planning software andstate-of-the-art Hands-On Robotics(TM), and Passive Constraint Navigation(TM)systems, Acrobot's products assist surgeons in achieving better patient outcomesby improving surgical precision and reducing surgical errors, while loweringoverall procedure cost. About Original Investments PLC Original Investments PLC, formerly called BioProjects International PLC, isquoted on the AIM market of the London Stock Exchange. The Company specializesin providing finance for early-stage companies that can demonstrate immediategrowth prospects and significant financial potential. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
15th Apr 201412:30 pmRNSSuspension
9th Apr 20141:55 pmRNSChange of Advisers and Registered Office
26th Mar 20143:16 pmRNSCompletion of VEC Transfer
21st Mar 20147:00 amRNSResignation of Dr. Robert Dean
19th Mar 20143:09 pmRNSReplacement announcement: Grant of options
19th Mar 201412:25 pmRNSGrant of options
7th Mar 20141:43 pmRNSHolding(s) in Company
7th Mar 20141:39 pmRNSHolding(s) in Company
27th Jan 20142:00 pmRNSResult of General Meeting
24th Jan 20143:22 pmRNSResult of Open Offer
7th Jan 20147:00 amRNSPlacing, Open Offer & Notice of General Meeting
4th Dec 20134:13 pmRNSResult of General Meeting
2nd Dec 20138:00 amRNSHalf Yearly Report
18th Nov 20131:30 pmRNSNotice of General Meeting & Proposed Board Changes
29th Oct 20133:31 pmRNSResult of AGM
29th Oct 20137:00 amRNSRestructure Proposals
30th Sep 20137:00 amRNSFinal Results
29th Aug 20139:00 amRNSNotice of AGM
19th Jun 20133:09 pmRNSExercise of Warrants & TVR
8th May 20137:00 amRNSContract Win
29th Apr 20137:00 amRNSBusiness & Technical Collaboration with CGG
16th Apr 20137:00 amRNSChange of Adviser
12th Apr 20137:00 amRNSChevron - precision subsurface mapping contract
8th Feb 20133:01 pmRNSPlacing of £1.4 million
7th Jan 20137:00 amRNSFiling of QuantumRD patents in nine countries
2nd Jan 20138:36 amRNSChevron Expands ViaLogy Contract
31st Dec 20127:00 amRNSHalf Yearly Report
19th Dec 20127:00 amRNSCEO Overview
21st Nov 20127:00 amRNSMove into Shale Oil Development
16th Nov 20127:00 amRNSNorth Sea Project Underway
1st Oct 20127:00 amRNSQuantumRD Services in China
20th Sep 20127:00 amRNSPresentation at Singapore Conference
23rd Jul 20121:50 pmRNSResult of AGM
29th Jun 20127:00 amRNSFinal Results
15th Jun 201211:25 amRNSResult of General Meeting
23rd May 20127:00 amRNSNotice of General Meeting
21st May 20127:00 amRNSPlacing
11th May 20129:30 amRNSIssue of Equity - Options Exercise
10th May 20127:00 amRNSBusiness Update
2nd May 201212:24 pmRNSContract Award
23rd Apr 20127:00 amRNSContract win
16th Apr 20127:00 amRNSSuccessful Texas Oil Well Drilled
12th Apr 20127:00 amRNSContract Win
14th Mar 20127:00 amRNSQuantumRD demonstration to Chevron
18th Jan 20127:00 amRNSPlacing and TVR
3rd Jan 20127:00 amRNSBusiness Update
30th Dec 20117:00 amRNSInterim Report & Accounts
28th Oct 201112:36 pmRNSResult of AGM
11th Oct 20113:28 pmRNSPlacing & TVR
30th Sep 20117:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.